Bibliographic information
Recommendation
In women who are pregnant or breastfeeding, weekly chemoprophylaxis with chloroquine can be given until delivery and breastfeeding are completed, then, on the basis of G6PD status, primaquine can be given to prevent future relapse.
Recommended in favor
Conditional
Certainty of evidence
Moderate
Notes and Remarks
Practical info Primaquine is contraindicated in pregnant women and in lactating women (unless the infant is known not to be G6PD deficient). As an alternative, chloroquine prophylaxis could be given to suppress relapses after acute vivax malaria during pregnancy. Once the infant has been delivered and the mother has completed breastfeeding, primaquine could then be given to achieve radical cure. Few data are available on the safety of primaquine in infancy, and in the past primaquine was not recommended for infants. There is, however, no specific reason why primaquine should not be given to children aged 6 months to 1 year (provided they do not have G6PD deficiency), as this age group may suffer multiple relapses from vivax malaria. The guideline development group therefore recommended lowering the age restriction to 6 months.
Also Featured In
This recommendation also appears in the following guidelines:
Guidelines for the treatment of malaria
WHO guidelines for malaria, 16 February 2021.
WHO guidelines for malaria, 13 July 2021.
WHO guidelines for malaria, 18 February 2022.
WHO guidelines for malaria, 31 March 2022.
WHO guidelines for malaria, 3 June 2022.
WHO guidelines for malaria, 25 November 2022.
WHO recommendations on maternal health: guidelines approved by the WHO Guidelines Review Committee, second edition. Geneva: World Health Organization; 2025
WHO Guidelines for malaria, 14 March 2023
WHO guidelines for malaria, 30 November 2024.
WHO guidelines for malaria, 13 August 2025